Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 26.10.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. WO2021041744 - ARYL BENZOYL IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF LUNG CANCER

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

What is claimed is:

1. A method of treating lung cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of formula XI:

wherein

X is a bond, NH or S;

Q is O, NH or S; and

A is substituted or unsubstituted single-, fused- or multiple-ring, aryl or (hetero)cyclic ring systems; substituted or unsubstituted, saturated or unsaturated N-heterocycles; substituted or unsubstituted, saturated or unsaturated S-heterocycles; substituted or unsubstituted, saturated or unsaturated O-heterocycles; substituted or unsubstituted, saturated or unsaturated cyclic hydrocarbons; or substituted or unsubstituted or saturated or unsaturated mixed heterocycles;

wherein said A ring is optionally substituted by 1-5 substituents which are independently O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, -CH2CN, NH2, hydroxyl, -(CH2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, -OCH2Ph, -NHCO-alkyl, COOH, -C(O)Ph, C(O)O-alkyl, C(O)H, -C(O)NH2 or NO2; and

i is an integer between 0-5,

wherein if Q is S, then X is not a bond,

or an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, N-oxide, or combinations thereof, to treat the lung cancer.

2. The method according to claim 1, wherein said compound is represented by the structure of formula VIII:


wherein

R4, R5 and R6 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, -CH2CN, NH2, hydroxyl, -(CH2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, -OCH2Ph, -NHCO-alkyl, COOH, -C(O)Ph, C(O)O-alkyl, C(O)H, -C(O)NH2 or NO2;

Q is S, O or NH;

i is an integer between 0-5; and

n is an integer between 1-3.

3. The method according to claim 1, wherein said compound is represented by the structure of formula XI(b):


wherein R4 and R5 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, -CH2CN, NH2, hydroxyl, -(CH2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -

OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, -OCH2Ph, -NHCO-alkyl, COOH, -C(O)Ph, C(O)O-alkyl, C(O)H, -C(O)NH2 or NO2;

i is an integer from 0-5; and

n is an integer between 1-4.

4. The method according to claim 1, wherein said compound is represented by the structure of formula XI(c):

wherein R4 and R5 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, -CH2CN, NH2, hydroxyl, -(CH2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, -OCH2Ph, -NHCO-alkyl, COOH, -C(O)Ph, C(O)O-alkyl, C(O)H, -C(O)NH2 or NO2;

i is an integer from 0-5; and

n is an integer between 1-4.

5. The method according to claim 4, wherein said compound is compound 55, represented by the structure:

or a pharmaceutically acceptable salt thereof.

6. The method according to claim 2, wherein said compound is (2-(phenylamino)thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (5a), (2-(p-tolylamino)thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (5b), (2-(p-fluorophenylamino)thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (5c), (2-(4-chlorophenylamino)thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (5d), or (2-(phenylamino)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (5e), or a pharmaceutically acceptable salt thereof.

7. The method according to claim 1, wherein the compound is combined with a pharmaceutically acceptable carrier.

8, The method according to claim 1, further comprising administering an additional cancer therapy.

9. A method of treating lung cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of formula XI(e):


wherein R4 and R5 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, -CH2CN, NH2, hydroxyl, -(CH2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, -OCH2Ph, -NHCO-alkyl, COOH, -C(O)Ph, C(O)O-alkyl, C(O)H, -C(O)NH2 or NO2;

i is an integer from 0-5; and

n is an integer between 1-4,

or an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, N-oxide, or combinations thereof, to a treat the lung cancer.

10. The method according to claim 9, wherein said compound is compound 17ya represented by the structure:


or a pharmaceutically acceptable salt thereof.

11. The method according to claim 9 further comprising an additional cancer therapy.